HSHC
禾伸堂生技股份有限公司
HSHC is a Taiwan Emerging Stock Board biotechnology company, as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| CA102N | — | Phase 2; suspended | Metastatic Colorectal Cancer | United States | 2026-09-18 | Trial registry |
| IBD98-M | — | Phase 2; completed | Colitis, Ulcerative | Italy | 2021-10-26 | Trial registry |
| ND108E | — | — | — | — | — | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.